3 March 2023 in Journal of the International Neuropsychological Society
Objective: Mild cognitive impairment (MCI) is an etiologically nonspecific diagnosis including a broad spectrum of cognitive decline between normal aging and dementia. Several large-scale cohort studies have found sex effects on neuropsychological test performance in MCI. The primary aim of the current project was to examine sex differences in neuropsychological profiles in a clinically diagnosed MCI sample using clinical and research diagnostic criteria.Method: The current study includes archival data from 349 patients (age M = 74.7; SD = 7.7) who underwent an outpatient neuropsychological evaluation and were diagnosed with MCI. Raw scores were converted to z-scores using normative datasets. Sex differences in neurocognitive profiles including severity, domain-specific composites (memory, executive functioning/information processing speed, and language), and modality-specific learning curves (verbal, visual) were examined using Analysis of Variance, Chi-square analyses, and linear mixed models. Post hoc analyses examined whether sex effects were uniform across age and education brackets.Results: Females exhibit worse non-memory domain and test-specific cognitive performances compared to males with otherwise comparable categorical MCI criteria and global cognition measured via screening and composite scores. Analysis of learning curves showed additional sex-specific advantages (visual Males>Females; verbal Females >Males) not captured by MCI subtypes.Conclusions: Our results highlight sex differences in a clinical sample with MCI. The emphasis of verbal memory in the diagnosis of MCI may result in diagnosis at more advanced stages for females. Additional investigation is needed to determine whether these profiles confer greater risk for progressing to dementia or are confounded by other factors (e.g., delayed referral, medical comorbidities).
26 September 2021 in Exploration of Targeted Anti-tumor Therapy
Aim: Smartphone technology is increasingly used by the public to assess sleep. Specific features of some sleep-tracking applications are comparable to actigraphy in objectively monitoring sleep. The clinical utility of smartphone apps should be investigated further to increase access to convenient means of monitoring sleep. Methods: Smartphone and subjective sleep measures were administered to 29 community-dwelling healthy adults [aged 20-67, Mean (M) = 26.8; 18 women, 11 men], and actigraphy to 19 of them. Total sleep time (TST) and sleep efficiency were measured with actigraphy and the Sleep Time app (Azumio Inc.). Sleep diaries captured subjective TST and sleep efficiency, and the Epworth Sleepiness Scale and Pittsburgh Sleep Quality Index provided self-report data. An exit questionnaire was administered to examine app feasibility and likelihood of future use. Results: The app significantly overestimated TST when compared to actigraphy. There was no significant difference in sleep efficiency between methodologies. There was also no significant difference between TST recorded through the app and through sleep diaries. Participants’ self-reported ease of use of the smartphone app positively correlated with likelihood of future use. Conclusions: Based on the current findings, future research is needed to investigate the utility and feasibility of multiple smartphone applications in monitoring sleep in healthy and clinical populations.
31 December 2025 in Journal of Clinical and Experimental Neuropsychology
Subjective cognitive decline (SCD) is an important yet heterogeneous indicator of mild cognitive impairment (MCI) and dementia. Sex and health-related disparities in risk are well established, but differences in prevalence and conversion rates from SCD to MCI/Dementia by risk factor remain unclear. This preregistered study followed PRISMA guidelines to conduct a systematic review with a narrative synthesis and meta-analyses. Random-effects meta-analyses calculated the relative risk (RR) of sex, depression, hypertension, and diabetes in conversion from SCD to MCI/dementia. Q and I2 statistics investigated heterogeneity. Prevalence rates were also calculated. Five cross-cultural studies (N = 1136) were eligible for the meta-analyses. Participants, on average, had less than 12 years of education. Pooled analyses showed no significant differences in the RR of conversion for depression, hypertension, or diabetes. The pooled conversion rate of SCD to MCI was 17.2% and 8.7% to dementia. Evidence of heterogeneity suggested that the aggregated data may mask differences between studies; thus, unpublished conversion rates on comorbid SCD and the health conditions are reported to inform future research. Relative risk estimates align with the greater literature and extend them to an inclusive cross-cultural sample with lower education. The significant heterogeneity found underscores the complexity of the interactions between cognitive decline and modifiable risk factors. This study provides novel conversion rates to MCI and dementia for individuals with comorbid SCD and depression, hypertension, and diabetes. We recommend that sex-stratified conversion rates are reported, as limited data prevented our meta-analysis from examining this important dimension of risk.